Implementation of Diabetes Mellitus Program in the Tyumen region

Aim. To assess results of realization of the regional Diabetes Mellitus Program in the Tyumen region. Materials and methods. Materials of the regional Diabetes Mellitus Registry for 1999-2007 were analysed. Results. DM1 and DM2 morbidity increased from 6.6 to 8.16 and from 97.3 to 216.96 per100,0...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lyudmila Alexandrovna Suplotova, L N Belchikova, N S Brynza
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2009
Materias:
Acceso en línea:https://doaj.org/article/bb910a1413bd4c57879ef0c8c29bdc77
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bb910a1413bd4c57879ef0c8c29bdc77
record_format dspace
spelling oai:doaj.org-article:bb910a1413bd4c57879ef0c8c29bdc772021-11-14T09:00:13ZImplementation of Diabetes Mellitus Program in the Tyumen region2072-03512072-037810.14341/2072-0351-5418https://doaj.org/article/bb910a1413bd4c57879ef0c8c29bdc772009-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5418https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To assess results of realization of the regional Diabetes Mellitus Program in the Tyumen region. Materials and methods. Materials of the regional Diabetes Mellitus Registry for 1999-2007 were analysed. Results. DM1 and DM2 morbidity increased from 6.6 to 8.16 and from 97.3 to 216.96 per100,000 population respectively. Primary disability rate among DM1 and DM2 patientsdecreased by a factor of 2. The fraction of patients with severe diabetic complications also decreased (1.3 times for blindness, 1.8 times for amputations). The frequency of diabeticcoma decreased by a factor of 2. Thirty five Diabetes School were organized. Mean life expectancy of DM1 and DM2 subjects increased from 49.55?5.43 to 50.11?2.96 years(p = 0.0001) and from 68.00?1.79 to 71.52?0.39 years (r = 0.0001) respectively. Mortality rate in DM1 and DM2 patients dropped by a factor of 5 and 3. All DM patients use onlymodern insulin formulations, with analogs accounting for 39.5% and human recombinant insulins for the rest of the total. Therapeutic use of secretagogues for the managementof DM2 decreased from 84.8 to 49.1% (p = 0.0001) and that of metformin increased form 6.8 to 28% (p = 0.0001); the need in insulin therapy also increased. Conclusion. Elaboration and implementation of the program contributed to the decreased occurrence of diabetic coma, blindness, and amputations in DM1 and DM2 patients,their longer life expectancy, and improved availability of high-quality oral hypoglycemic agents.Lyudmila Alexandrovna SuplotovaL N BelchikovaN S BrynzaEndocrinology Research Centrearticlediabetes mellitusregional registrymorbiditydisabilitycomplicationsmortalityNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 12, Iss 1, Pp 33-35 (2009)
institution DOAJ
collection DOAJ
language EN
RU
topic diabetes mellitus
regional registry
morbidity
disability
complications
mortality
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle diabetes mellitus
regional registry
morbidity
disability
complications
mortality
Nutritional diseases. Deficiency diseases
RC620-627
Lyudmila Alexandrovna Suplotova
L N Belchikova
N S Brynza
Implementation of Diabetes Mellitus Program in the Tyumen region
description Aim. To assess results of realization of the regional Diabetes Mellitus Program in the Tyumen region. Materials and methods. Materials of the regional Diabetes Mellitus Registry for 1999-2007 were analysed. Results. DM1 and DM2 morbidity increased from 6.6 to 8.16 and from 97.3 to 216.96 per100,000 population respectively. Primary disability rate among DM1 and DM2 patientsdecreased by a factor of 2. The fraction of patients with severe diabetic complications also decreased (1.3 times for blindness, 1.8 times for amputations). The frequency of diabeticcoma decreased by a factor of 2. Thirty five Diabetes School were organized. Mean life expectancy of DM1 and DM2 subjects increased from 49.55?5.43 to 50.11?2.96 years(p = 0.0001) and from 68.00?1.79 to 71.52?0.39 years (r = 0.0001) respectively. Mortality rate in DM1 and DM2 patients dropped by a factor of 5 and 3. All DM patients use onlymodern insulin formulations, with analogs accounting for 39.5% and human recombinant insulins for the rest of the total. Therapeutic use of secretagogues for the managementof DM2 decreased from 84.8 to 49.1% (p = 0.0001) and that of metformin increased form 6.8 to 28% (p = 0.0001); the need in insulin therapy also increased. Conclusion. Elaboration and implementation of the program contributed to the decreased occurrence of diabetic coma, blindness, and amputations in DM1 and DM2 patients,their longer life expectancy, and improved availability of high-quality oral hypoglycemic agents.
format article
author Lyudmila Alexandrovna Suplotova
L N Belchikova
N S Brynza
author_facet Lyudmila Alexandrovna Suplotova
L N Belchikova
N S Brynza
author_sort Lyudmila Alexandrovna Suplotova
title Implementation of Diabetes Mellitus Program in the Tyumen region
title_short Implementation of Diabetes Mellitus Program in the Tyumen region
title_full Implementation of Diabetes Mellitus Program in the Tyumen region
title_fullStr Implementation of Diabetes Mellitus Program in the Tyumen region
title_full_unstemmed Implementation of Diabetes Mellitus Program in the Tyumen region
title_sort implementation of diabetes mellitus program in the tyumen region
publisher Endocrinology Research Centre
publishDate 2009
url https://doaj.org/article/bb910a1413bd4c57879ef0c8c29bdc77
work_keys_str_mv AT lyudmilaalexandrovnasuplotova implementationofdiabetesmellitusprograminthetyumenregion
AT lnbelchikova implementationofdiabetesmellitusprograminthetyumenregion
AT nsbrynza implementationofdiabetesmellitusprograminthetyumenregion
_version_ 1718429676131581952